Hrt Financial LP Cellectis S.A. Transaction History

Hrt Financial LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$14.36 - $20.93 $251,098 - $365,981	-17,486 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$18.19 - $33.25 $127,311 - $232,716	-6,999 Reduced 28.58%	17,486 $353,000
Q4 2020 Feb 16, 2021	BUY	$15.87 - $31.64 $388,576 - $774,705	24,485 New	24,485 $662,000

11.2M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $96.9M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.